Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2015

Open Access 01-12-2015 | Study protocol

A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial

Authors: Philippe Martin, Robyn Tamblyn, Sara Ahmed, Andrea Benedetti, Cara Tannenbaum

Published in: Trials | Issue 1/2015

Login to get access

Abstract

Background

Medication safety for older persons represents an ongoing challenge. Inappropriate prescriptions – those with a high risk of evidence-based harm – persist in up to 25 % of seniors, and account for a significant proportion of avoidable emergency department visits. This project is the sequel to the EMPOWER study, in which a novel consumer-targeted written knowledge transfer tool aimed at empowering older adults to act as drivers of benzodiazepine de-prescription resulted in a 27 % reduction of inappropriate benzodiazepine use at 6-month follow-up (number needed to treat (NNT) = 4). Failure to discontinue in the EMPOWER study was attributable to re-emerging symptoms among participants, prescribing inertia, and lack of knowledge and skills for substituting alternate therapy among physicians and pharmacists. To maximize de-prescription of inappropriate therapy, educational medication-risk reduction initiatives should be tested that simultaneously include patients, physicians and pharmacists. The objective of this trial is to: 1) test the beneficial effect of a new de-prescribing paradigm enlisting pharmacists to transfer knowledge to both patients and prescribers in a 2-pronged approach to reduce inappropriate prescriptions, compared to usual care and 2) evaluate the transferability of the EMPOWER study concept to other classes of inappropriate prescriptions.

Methods

We intend to conduct a 3-year pragmatic cluster randomized parallel-group controlled trial to test the effect of the new de-prescribing intervention compared to usual care for reducing 4 classes of inappropriate prescriptions from the 2012 Beers criteria among 450 community-dwelling older adults with polypharmacy. Inappropriate prescriptions will include benzodiazepines, sulfonylurea hypoglycemic agents, first generation antihistamines and non-steroidal anti-inflammatory drugs. The study population is community-dwelling older adults recruited from community pharmacies in Quebec, Canada. The intervention was developed based on a systematic review of the evidence for each medication. Participants in the experimental group will receive the written educational program following randomization and have their pharmacist send their physicians an evidence-based pharmaceutical opinion to recommend de-prescription and be followed for a year. The control group will be wait-listed for 6 months.

Discussion

System change to effectively reduce medication risk among community-dwelling seniors requires a coordinated approach targeting physicians, pharmacists and patients. This trial will test the feasibility and effectiveness of a tripartite approach to de-prescribing.

Trial registration

Registered via ClinicalTrials.gov on 31 January 2014, identifier: NCT02053194.
Appendix
Available only for authorised users
Literature
1.
Tannenbaum C. Effect of age, education and health status on community dwelling older men’s health concerns. Aging Male. 2012;15(2):103–8.CrossRefPubMed
2.
Tannenbaum C, Mayo N, Ducharme F. Older women’s health priorities and perceptions of care delivery: results of the WOW health survey. CMAJ. 2005;173(2):153–9.CrossRefPubMedPubMedCentral
3.
Reeve E, Wiese MD, Hendrix I, et al. People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc. 2013;61(9):1508–14.CrossRefPubMed
4.
Reason B, Terner M, Moses McKeag A, et al. The impact of polypharmacy on the health of Canadian seniors. Fam Pract. 2012;29(4):427–32.CrossRefPubMed
5.
Terner M, Reason B, McKeag AM, et al. Chronic conditions more than age drive health system use in Canadian seniors. Healthc Q. 2011;14(3):19–22.CrossRefPubMed
6.
Lorgunpai SJ, Grammas M, Lee DS, et al. Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition. PLoS ONE. 2014;9(2), e89447.CrossRefPubMedPubMedCentral
7.
Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62(12):2261–72.CrossRefPubMedPubMedCentral
8.
Gomez C, Vega-Quiroga S, Bermejo-Pareja F, et al. Polypharmacy in the elderly: a marker of increased risk of mortality in a population-based prospective study (NEDICES). Gerontology. 2014.
9.
American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRef
10.
Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113–21.CrossRefPubMed
11.
McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ. 1997;156(3):385–91.PubMedPubMedCentral
12.
Information CIfH. In: Information CIfH editor. Drug use among seniors on public drug programs in Canada. Ottawa, ON: CIHI; 2014.
13.
Kaur S, Mitchell G, Vitetta L, et al. Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging. 2009;26(12):1013–28.CrossRefPubMed
14.
Tamblyn R, Eguale T, Buckeridge DL, et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial. J Am Med Inform Assoc. 2012;19(4):635–43.CrossRefPubMedPubMedCentral
15.
Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.CrossRefPubMed
16.
Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793–807.CrossRefPubMed
17.
Martin P, Tamblyn R, Ahmed S, et al. An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials. 2013;14:80.CrossRefPubMedPubMedCentral
18.
Monane M, Matthias DM, Nagle BA, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA. 1998;280(14):1249–52.CrossRefPubMed
19.
Brekke M, Rognstad S, Straand J, et al. Pharmacologically inappropriate prescriptions for elderly patients in general practice: how common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care. 2008;26(2):80–5.CrossRefPubMedPubMedCentral
20.
Médicament Cd. Étude sur la prévalence de l’usage d’ordonnances potentiellement non appropriées (OPNA) chez les aînés du Québec, de 2000 à 2006. In: Médicament Cd, editor. Gouvernement du Québec; 2009.
21.
Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull. 1988;24(4):689–92.PubMed
22.
23.
Prochaska JO, Norcross JC, Diclemente CC. Changing for good: the revolutionary program that explains the six stages of change and teaches you how to free yourself from bad habits. New York: Morrow; 1994.
24.
Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655.CrossRefPubMedPubMedCentral
25.
Stewart R, Niessen WJ, Broer J, et al. General Practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application. J Clin Epidemiol. 2007;60(10):1076–84.CrossRefPubMed
26.
Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 2005;78(1):49–56.CrossRefPubMed
27.
Holden JD, Hughes IM, Tree A. Benzodiazepine prescribing and withdrawal for 3234 patients in 15 general practices. Fam Pract. 1994;11(4):358–62.CrossRefPubMed
28.
Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract. 1994;44(386):408–12.PubMedPubMedCentral
29.
Patterson SM, Hughes C, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev (Online). 2012;5:CD008165.
30.
Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. Int J Epidemiol. 2006;35(5):1292–300.CrossRefPubMed
31.
Dupont WD, Plummer Jr WD. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2):116–28.CrossRefPubMed
32.
Ukoumunne OC, Forbes AB, Carlin JB, et al. Comparison of the risk difference, risk ratio and odds ratio scales for quantifying the unadjusted intervention effect in cluster randomized trials. Stat Med. 2008;27(25):5143–55.CrossRefPubMed
33.
34.
Tinetti ME, Basch E. Patients’ responsibility to participate in decision making and research. JAMA. 2013;309(22):2331–2.CrossRefPubMed
35.
Zou D, Tannenbaum C. Educational needs, practice patterns and quality indicators to improve geriatric pharmacy care. Can Pharm J. 2014;147(2):110–7.CrossRef
36.
Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.CrossRefPubMedPubMedCentral
37.
Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260–8.PubMed
38.
Rummans TA, Davis Jr LJ, Morse RM, et al. Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients. Mayo Clin Proc. 1993;68(8):731–7.CrossRefPubMed
39.
Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012;29(8):639–58.PubMed
40.
Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc. 2002;50(10):1629–37.CrossRefPubMed
41.
Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci. 2005;60(5):622–6.CrossRefPubMed
42.
Coutinho ES, Fletcher A, Bloch KV, et al. Risk factors for falls with severe fracture in elderly people living in a middle-income country: a case control study. BMC Geriatr. 2008;8:21.CrossRefPubMedPubMedCentral
43.
Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc. 2005;53(2):233–41.CrossRefPubMed
44.
Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262(23):3303–7.CrossRefPubMed
45.
Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17(11):825–37.CrossRefPubMed
46.
Finkle WD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc. 2011;59(10):1883–90.CrossRefPubMed
47.
Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352(9137):1331–6.CrossRefPubMed
48.
Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician. 1998;44:799–808.PubMedPubMedCentral
49.
Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278(1):27–31.CrossRefPubMed
50.
51.
52.
Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–7.CrossRefPubMed
53.
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev (Online). 2010;12:CD006815.
54.
Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099–105.CrossRefPubMed
55.
Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.CrossRefPubMed
56.
Gnjidic D, Bell JS, Hilmer SN, et al. Drug Burden Index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44(5):458–67.CrossRefPubMed
57.
58.
Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–12.CrossRefPubMed
59.
Gangji AS, Cukierman T, Gerstein HC, et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30(2):389–94.CrossRefPubMed
60.
Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751–5.CrossRefPubMed
61.
Clarke BF, Campbell IW. Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics. Lancet. 1975;1(7901):246–8.CrossRefPubMed
62.
Bramlage P, Gitt AK, Binz C, et al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012;11:122.CrossRefPubMedPubMedCentral
63.
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46.CrossRef
64.
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731–8.CrossRefPubMedPubMedCentral
65.
Pilotto A, Franceschi M, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res. 2003;15(6):494–9.CrossRefPubMed
66.
Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24.CrossRef
67.
Plowright R, Witthaus E, Bradley C. Psychometric evaluation of Diabetes Treatment Satisfaction Questionnaire in 8 languages. Proc Br Psychological Soc. 2000;8(2).
68.
Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed
69.
Reeve E, Shakib S, Hendrix I, et al. Development and validation of the patients’ attitudes towards deprescribing (PATD) questionnaire. Int J Clin Pharm. 2013;35(1):51–6.CrossRefPubMed
70.
Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRefPubMed
71.
Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691–9.CrossRefPubMed
Metadata
Title
A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trial
Authors
Philippe Martin
Robyn Tamblyn
Sara Ahmed
Andrea Benedetti
Cara Tannenbaum
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue 1/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-015-0791-1

Other articles of this Issue 1/2015

Trials 1/2015 Go to the issue

Study protocol

The Community In-Reach and Care Transition (CIRACT) clinical and cost-effectiveness study: study protocol for a randomised controlled trial

Study protocol

Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial

Methodology

A sample size planning approach that considers both statistical significance and clinical significance

Study protocol

Effect of a multifaceted educational program for care staff concerning fecal incontinence in nursing home patients: study protocol of a cluster randomized controlled trial

Study protocol

Preventing anxiety problems in children with Cool Little Kids Online: study protocol for a randomised controlled trial

Methodology

Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening